Two Sigma Investments LP Has $1.04 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Two Sigma Investments LP lowered its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 54.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 98,078 shares of the company's stock after selling 115,987 shares during the quarter. Two Sigma Investments LP owned 0.10% of ARS Pharmaceuticals worth $1,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Rafferty Asset Management LLC grew its holdings in ARS Pharmaceuticals by 72.7% during the 4th quarter. Rafferty Asset Management LLC now owns 140,372 shares of the company's stock worth $1,481,000 after acquiring an additional 59,097 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of ARS Pharmaceuticals by 22.9% during the fourth quarter. ProShare Advisors LLC now owns 18,463 shares of the company's stock worth $195,000 after purchasing an additional 3,436 shares during the period. Panoramic Capital LLC acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter worth $483,000. Millennium Management LLC grew its stake in shares of ARS Pharmaceuticals by 93.0% in the fourth quarter. Millennium Management LLC now owns 939,278 shares of the company's stock worth $9,909,000 after purchasing an additional 452,532 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ARS Pharmaceuticals by 11.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,560 shares of the company's stock worth $354,000 after purchasing an additional 3,327 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

ARS Pharmaceuticals Stock Up 0.3%

ARS Pharmaceuticals stock traded up $0.04 during trading hours on Monday, reaching $14.53. 1,067,421 shares of the company's stock were exchanged, compared to its average volume of 1,285,688. The firm's 50 day simple moving average is $13.97 and its 200 day simple moving average is $12.81. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The firm has a market capitalization of $1.43 billion, a PE ratio of -28.49 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. Analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Insider Activity

In other ARS Pharmaceuticals news, Director Brent L. Saunders sold 120,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total value of $1,710,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Eric Karas sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at $107,744. The trade was a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 332,971 shares of company stock worth $4,621,888 in the last quarter. 33.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on SPRY. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price on the stock. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Wall Street Zen lowered ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.